Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VIVO Cannabis Inc. VVCIF

Healthcare Drug Manufacturers - Specialty & Generic
VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.


OTCQB:VVCIF - Post by User

VIVO Cannabis Inc. > The Trouble with Q4
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(182)
•••
Comment by srtman03on Feb 01, 2020 8:11am
262 Views
Post# 30628688

RE:The Trouble with Q4

RE:The Trouble with Q4
Ruprecht wrote: The trouble with Q4 is that there seem to be no revenue catalysts in that quarter, while on the other hand, the company continued capital investment to complete expansion activities.  All in all I see an underwhelming Q4.  Unfortuneately, due to the frothiness and expectations created in January this will apply drag to the shareprice.  I think that shareprice will hold at 0.24-0.28 despite the dissapointment.
 

Another new fear spreading idiot...LOL
..............................................................................................................................................................................................................................

VIVO's net revenue increased to $6.3 million during Q3 2019, a 19% increase relative to Q2 2019, reflecting the ramp-up of the Company's increased licenced capacity which is expected to result in further revenue growth in Q4 2019. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities